Amendment No. 1 to Third Amended and Restated Investor Promissory Note issued by the Company
Contract Categories:
Business Finance
- Note Agreements
EX-4.8 5 g083766_ex4-8.htm EXHIBIT 4.8
Exhibit 4.8
CHROMOCELL THERAPEUTICS CORPORATION
Amendment No. 1 to Third Amended and Restated Promissory Note
| Face Amount: $450,000.00 | September 26, 2023 |
| Purchase Price: $300,000.00 | New York, NY |
Chromocell Therapeutics Corporation, a Delaware corporation (the “Borrower”), and 3i, LP, its successors or assigns (the “Lender”), pursuant to that certain Third Amended and Restated Promissory Note, dated August 13, 2023 (the “Note”), do hereby agree to amend the Note to extend the Maturity Date (as defined in the Note) to October 10, 2023.
In consideration thereof, the Company agrees to pay to Lender the amount of One Hundred Dollars ($100).
Except as specifically set forth herein, Borrower and Lender hereby confirm that the terms of the Note remain unmodified and in full force and effect.
| BORROWER: | |||
| Chromocell Therapeutics Corporation | |||
| By: | /s/ Francis Knuettel II | ||
| Name: Francis Knuettel II | |||
| Title: Chief Financial Officer | |||
| LENDER: | |||
| 3i, LP | |||
| By: | /s/ Maier J. Tarlow | ||
| Name: Maier J. Tarlow | |||
| Title: Manager On Behalf Of The GP | |||
